Researchers have uncovered new genetic rules that determine how CD8 killer T cells choose between becoming long-lasting, protective defenders or slipping into exhausted, dysfunctional states.
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving their therapeutic effectiveness. The study suggests new strategies for improving the efficacy of these immune cells, known as chimeric antigen receptor T cells.
